DSIP vs Semaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Full details →Side-by-Side Comparison
| Aspect | DSIP | Semaglutide |
|---|---|---|
| Mechanism | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. | Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control. |
| Typical Dosage | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. | Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary. |
| Administration | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. | Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects. |
| Side Effects | May cause grogginess upon waking, vivid dreams, or temporary headaches. | Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions. |
| Best For |